v3.26.1
Organization and Description of the Business (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 06, 2026
USD ($)
Nov. 06, 2025
Oct. 31, 2025
Mar. 31, 2026
USD ($)
segment
$ / shares
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
$ / shares
Mar. 30, 2026
shares
$ / shares
Organization And Description Of Business [Line Items]              
Number of operating segments | segment       1      
Common stock, par value (in dollars per share) | $ / shares       $ 0.001   $ 0.001  
Initial upfront payments total $ 1,000            
Development and commercial milestone amount to be received $ 127,000            
Accumulated deficit       $ 496,288   $ 490,532  
Restructuring and related cost, number of positions eliminated, period percent   70.00% 70.00%        
Restructuring charges       612   $ 6,837  
Restructuring and impairment charges       $ 612 $ 0    
Minimum              
Organization And Description Of Business [Line Items]              
Sufficient cash and cash equivalents available period term       12 months      
Aurinia Pharma U.S., Inc. | Kezar Life Sciences Inc              
Organization And Description Of Business [Line Items]              
Common stock, par value (in dollars per share) | $ / shares             $ 0.001
Business combination, price per share (usd per share) | $ / shares             $ 6.955
Number of contingent value rights (in shares) | shares             1